GPN Vaccines is a public (unlisted) biotechnology company developing a vaccine against Streptococcus pneumoniae, the bacteria responsible for causing life-threatening pneumonia, bacteraemia and meningitis, as well as otitis media (middle ear infections). Each year it causes 1-2 million deaths worldwide, killing more children than AIDS, malaria and tuberculosis combined. There are now 100 different strains of S. pneumoniae, however the best vaccine currently on the market only protects against 13 strains. Our vaccine, Gamma-PN, is being developed to protect children and adults against all strains of S. pneumoniae.
Location: Australia, South Australia, Adelaide
Employees: 11-50
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Shearwater... | shearwater... |
Mentions in press and media 2
| Date | Title | Description |
| 18.09.2024 | Just what the doctor ordered: 24 Aussie health tech startups that raised millions in 2024 | Some of the many Australian founders who have raised millions in funding this year. Source: SmartCompany. article-article-body There’s plenty to get excited about when it comes to health tech in Australia. From pioneering treatments for foo... |
| - | GPN Vaccines | “GPN Vaccines | Developing a Universal Pneumococcal Vaccine” |